hla-a2-restricted peptides + Montanide ISA51

This is a combination immunotherapeutic formulation consisting of HLA-A2-restricted peptides emulsified in Montanide ISA51. HLA-A2-restricted peptides are short synthetic peptide antigens designed to be presented by the HLA-A*02 major histocompatibility complex class I molecule, commonly used in cancer vaccine and immunotherapy research to elicit cytotoxic T lymphocyte (CTL) responses against tumor-associated or viral antigens. Montanide ISA51 is a water-in-oil emulsion adjuvant composed of highly purified mineral oil and mannide monooleate surfactant, used to enhance immune responses by promoting antigen uptake and presentation. The combination is typically administered as a therapeutic cancer vaccine or experimental immunotherapy, aiming to induce robust CD8+ T cell-mediated immunity against specific targets[4][5][1]. The mechanism involves enhanced antigen delivery and stimulation of both humoral and cellular immune responses.